ClinicalTrials.gg
Active, not recruitingNCT07428759Updated Oct 27, 2026

Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years

A Phase 1 interventional study of Pn-MAPS30plus and PCV20 in Pneumonia, Bacterial, sponsored by GlaxoSmithKline. Active, not recruiting at 2 sites in Australia. Open to participants aged 50 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Prevention

Updated Oct 27, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
50 Years to 64 Years
Sex
All
01

Study summary

This study will evaluate the safety and immune response of a new formulation of pneumococcal vaccine, PnMAPS30plus, in healthy adults aged 50 to 64 years. Participants will receive a single dose of either the investigational vaccine or an approved pneumococcal vaccine (PCV20) and will be monitored for approximately six months. The study aims to determine if PnMAPS30plus is safe and well-tolerated and whether it helps the body produce antibodies that protect against pneumococcal disease.

02

Conditions studied

  • Pneumonia, Bacterial

Browse trials for

Keywords

  • Pn-MAPS30plus
  • MAPS technology
  • pneumococcal vaccine
  • Phase 1
  • Healthy Adults
  • 50-64 years
03

In context

Pneumonia, Bacterial

153 studies on the registry are indexed under Pneumonia, Bacterial; 27 are open to participants now.

This study's enrollment of 122 is close to the median of 132 across 107 interventional studies indexed under Pneumonia, Bacterial.

Browse Pneumonia, Bacterial studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who, in the opinion of the investigator, can comply with the requirements (e.g., completion of the electronic diary [eDiary], return for follow-up visits).
  2. Written or witnessed/thumb printed obtained before any trial-specific procedure.
  3. Healthy or medically stable adults confirmed by medical history and clinical examination at screening. Participants with stable medical conditions can be enrolled at the discretion of the investigator.
  4. Male and female participants aged 50 and 64 years of age (YOA) at the time of Informed consent form (ICF) signature.
  5. Female participants of (POCBP) may enrol if they practice adequate and have a negative pregnancy test prior to study intervention administration.

Exclusion criteria

Exclusion Criteria:

  1. History of microbiologically proven invasive pneumococcal disease (IPD) caused by S. pneumoniae within 3 years before study intervention administration.
  2. History of any reaction or likely to be exacerbated by any component of the study intervention(s).
  3. Any confirmed or suspected or immunodeficient condition.
  4. Hypersensitivity to latex.
  5. Clinical conditions representing a to intramuscular vaccination, and blood collection.
  6. Documented -positive status.
  7. Acute or unstable chronic pulmonary, cardiovascular, hepatic or renal functional abnormality, or metabolic conditions as determined by the investigator.
  8. Recurrent history of uncontrolled neurological or any neuroinflammatory disorders.
  9. Any behavioural or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the trial.
  10. Any other clinical condition that, might pose additional risk to the participant.
  11. Use of any or non-registered product other than the study interventions within 30 days before the study intervention administration.
  12. History of previous vaccination with any pneumococcal vaccine.
  13. Administration of immunoglobulins or other blood products or plasma derivatives within 90 days before or planned within 30 days after study intervention.
  14. Chronic administrations of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the trial.
  15. Pregnant or lactating female participant.
  16. History of and/or current chronic alcohol consumption and/or drug abuse, based on investigator judgment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    Group 1: Pn- MAPS30plus

    Participants receive a single dose of Pn-MAPS30plus vaccine at Day 1.

    Biological: Pn-MAPS30plus

  • Active comparator
    Group 2: PCV20

    Participants receive a single dose of PCV20 (20-valent pneumococcal conjugate vaccine) at Day 1.

    Combination Product: PCV20

Interventions

  • BiologicalPn-MAPS30plus

    Single dose of Pn-MAPS30plus received intramuscularly.

  • Combination productPCV20

    Single dose of PCV20 received intramuscularly.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Solicited Administration Site Adverse Events (AEs)

    The solicited administration site AEs considered are pain, redness and swelling.

    Time frame: Day 1 to Day 7

  2. Number of Participants with Solicited Systemic AEs

    The solicited systemic AEs considered are fever, headache, fatigue (tiredness), myalgia (muscle pain), and arthralgia (joint pain).

    Time frame: Day 1 to Day 7

  3. Number of Participants with Unsolicited AEs

    An unsolicited AE is an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events.

    Time frame: Day 1 to Day 30

  4. Number of Participants with Serious Adverse Events (SAEs)

    SAE is an AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or other situations that are considered serious per medical or scientific judgment.

    Time frame: From Day 1 to Day 181 (study end)

  5. Number of Participants with Adverse Events of Special Interest (AESIs)

    Time frame: From Day 1 to Day 181 (study end)

  6. Number of Participants with AEs Leading to withdrawal from the study

    Time frame: From Day 1 to Day 181 (study end)

  7. Number of Participants with any Laboratory abnormalities

    Time frame: Day 8 compared to Screening Visit (up to Day -14)

07

Study locations

2 sites
  • GSK Investigational Site
    Norwood, South Australia 5067, Australia
  • GSK Investigational Site
    Camberwell, Victoria 3124, Australia
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2026 (actual). Primary completion is estimated for Nov 2026, 8 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Dec 2026 → Nov 2026 and completion Dec 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2026
First posted
Feb 24, 2026
StartActual
Mar 10, 2026
Primary completionEst.
Nov 19, 2026was Dec 2026
CompletionEst.
Nov 19, 2026was Dec 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 9, 2026→Nov 19, 2026
Oct 27, 2026
Study completion
Dec 9, 2026→Nov 19, 2026
Oct 27, 2026
Enrollment
121→122
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Primary completion Dec 9, 2026→Nov 19, 2026
    Study completion Dec 9, 2026→Nov 19, 2026
    Enrollment 121→122
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07428759
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
Mar 10, 2026
Primary completion
Nov 19, 2026 (estimated)
Completion
Nov 19, 2026 (estimated)
Last update
Oct 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pn-MAPS30plus

Start the discussion